In recent years, it has been increasingly clear that long non-coding RNAs (lncRNAs) are able to regulate their target genes at multi-levels, including transcriptional level, translational level, etc and play key regulatory roles in many important biological processes, such as cell differentiation, chromatin remodeling and more. Inferring potential lncRNA-disease associations is essential to reveal the secrets behind diseases, develop novel drugs, and optimize personalized treatments. However, biological experiments to validate lncRNA-disease associations are very time-consuming and costly. Thus, it is critical to develop effective computational models. In this study, we have proposed a method by alternating least squares based on matrix factorization to predict lncRNA-disease associations, referred to as ALSBMF. ALSBMF first decomposes the known lncRNA-disease correlation matrix into two characteristic matrices, then defines the optimization function using disease semantic similarity, lncRNA functional similarity and known lncRNAdisease associations and solves two optimal feature matrices by least squares method. The two optimal feature matrices are finally multiplied to reconstruct the scoring matrix, filling the missing values of the original matrix to predict lncRNA-disease associations. Compared to existing methods, ALSBMF has the same advantages as BPLLDA. It does not require negative samples and can predict associations related to novel lncRNAs or novel diseases. In addition, this study performs leave-one-out cross-validation (LOOCV) and five-fold cross-validation to evaluate the prediction performance of ALSBMF. The AUCs are 0.9501 and 0.9215, respectively, which are better than the existing methods. Furthermore colon cancer, kidney cancer, and liver cancer are selected as case studies. The predicted top three colon cancer, kidney cancer, and liver cancer-related lncRNAs were validated in the latest LncRNADisease database and related literature. In order to test the ability of ALSBMF to predict novel disease-associated lncRNAs and new lncRNA-associated diseases, all known associations of diseases and lncRNAs were eliminated, the predicted top five breast cancer, nasopharyngeal carcinoma cancer-related lncRNAs and top five H19, MALAT1 lncRNA-related cancers were validated in PubMed and dbSNP.
I. INTRODUCTION
Sequence analysis of the human genome identified only 20,000 coding sequences that can be translated into proteins, The associate editor coordinating the review of this manuscript and approving it for publication was Kin Fong Lei . and the number of these coding sequences accounted for less than 2% of all human genomes (Paul et al., 2004) . Most noncoding region gene sequences can transcribe and generate tens of thousands of non-coding RNAs (ncRNAs) (Yuan et al., 2013) . Non-coding RNAs are RNAs that cannot be translated into proteins. However, they cannot be considered to have no effect and do not contain any useful information. Many recent studies have found that ncRNAs are significant in regulating many crucial biological processes, for instance, apoptosis and cell cycle, translational control, and epigenetic regulation and splicing regulation. Depending on their length, ncRNAs can be divided into long non-coding RNAs (lncRNA) (Pauli et al., 2011 ) and short non-coding RNAs. LncRNA is an ncRNA with the length of greater than 200 nucleotides. In the latest research, it is recognized that an increasing number of lncRNAs have been founded in eukaryotes due to advanced sequencing technologies and computer models. Research evidence suggests that lncRNA is critical in important biological processes such as cell proliferation, cell differentiation, chromatin remodeling and transcription (Guttman et al., 2009 ). The development of many diseases is associated with disorders of lncRNA, such as diabetes (Pasmant et al., 2011) , cardiovascular disease (Congrains et al., 2012) , and few cancers, for example, lung cancer (Ji et al., 2003) and breast cancer (Barsytelovejoy et al., 2006) . Therefore, the recent authentication of lncRNA-disease associations has been a popular research issue, and more and more crucial disease-associated lncRNAs have been founded. For instance, through quantitative PCR studies, it has been found that breast cancer metastasis patients have approximately 100 to 2000 times the expression of HOTAIR, which is higher than that of fit persons (Gupta et al., 2010) . LncRNA HOTAIR is related with the transfer and progress of other carcinomas, for instance, carcinomas of livers (Hrdlickova et al., 2014) and carcinomas of lungs . Hence, HOTAIR is considered to be an underlying biological marker for cancer (Maass et al., 2014) . Besides, the dysfunction of lncRNA H19 is discovered in some illness, for instance, bladder cancer (Ariel et al., 2000) . Based on the knock-down study, down-regulation of H19 also significantly reduced colony formation and anchorage-independent growth of breast cancer cells (Barsytelovejoy et al., 2006) . Some databases have saved many known lncRNA-disease associations that include LncRNADisease(Chen et al., 2013), Lnc2Cancer (Ning et al., 2016) , MNDR (Wang et al., 2013) , and more, which lay a solid foundation for forecasting novel correlations by efficient computing means. In a general way, the computational models that forecast lncRNA-disease correlations are sorted to three classes which contain machine learning-based models, network-based models and known disease related to gene/miRNA-based models (Chen et al., 2017) . The machine learning-based models are constructed using training samples (known diseaseassociated lncRNA) or unlabeled samples (lncRNA-disease association without any known associated evidence) to predict potential lncRNA-disease associations. For example, Zhao et al. developed a naive Bayesian classifier (Zhao et al., 2015) to predict the associations of lncRNAs and diseases by combining regulatory groups, genomes and transcriptomes on the basis of known cancer-associated lncRNAs. Finally, the method captures 707 potential lncRNA-cancer associations that show superior performance. An important disadvantage of this method is that it requires information on negative samples, which is unknown in this field of study. To solve this problem, Chen et al. identified a candidate lncRNA-disease association by establishing a Laplacian regularized least squares method based on a semi-supervised learning framework (Chen and Yan, 2013) . This method is simply called LRLSLDA. LRLSLDA was first used based on a basic hypothesis that ''a disease with similarity is associated with a lncRNA that is also functionally similar, and vice versa'' to identify lncRNA-disease relations. It combines the known lncRNA-disease association with the expression profile of lncRNA to select candidates for disease-associated lncRNA, and it does not use negative samples. However, LRLSLDA still has some limitations, namely how to choose the best parameters.
A similarity network-based model is a global-based similarity network model by integrating known lncRNAdisease-associated networks, disease similarity networks, and lncRNA similarity networks to build heterogeneous networks, then discovers the potential association between lncRNAs and diseases in heterogeneous networks. However, majority of ways can not be used to novel diseases (without any known related lncRNA) and to novel lncRNAs (without any known related diseases and known miRNA reciprocity companies). For instant, Sun et al. (Sun et al., 2014) putted forward a computational mean called RWRlncD based on lncRNA-disease relation, lncRNA similarity and disease similarity. This algorithm performs a restart random walk (RWR) in the functional similarity network of lncRNA to capture latent lncRNA-disease associations. Nevertheless, this method cannot predict isolated lncRNA-related diseases. Gu et al. (Gu et al., 2017) used the global network random walk model to predict lncRNA-disease associations (GrwLDA). GrwLDA is a network of similarities that uses known lncRNA-disease associations, disease similarity and lncRNA similarity to restart improved random walks in the functional similarities and disease similarities network of lncRNA for predicting potential lncRNA-disease associations. This method can reveal unknown lncRNA-associated diseases and lncRNAs associated with unknown diseases. However, GrwLDA has some drawbacks, such as how to choose the optimal parameters.
In both of the above parts, all computational models require a known lncRNA-disease association for the prediction. Nevertheless, even now, the number of associations in biological experiments that identify lncRNA-diseases is also very restricted. Hence, investigators began to predict lncRNA-disease associations by integrating miRNA-disease associations and lncRNA-miRNA interactions (Chen X,2015) . Because a large number of disease semantic similarity, miRNA-disease associations, and miRNA-lncRNA interactions have been saved, some researchers can use known disease-associated genes to predict lncRNA-disease associations. Liu et al. (Ming-Xi et al., 2014) first found that it was neccessary to depend on known lncRNA-disease associations to explain the associations between these lncRNAs and the corresponding diseases. In addition, it can obtain non-tissue-specific lncRNA-related diseases based on disease-gene association and gene-lncRNA co-expression relationships. The method achieves better prediction performance. However, this method cannot predict the associated lncRNA of a disease without a related gene record. putted forward a computational approach based on genomic mapping to comprehensively screen lncRNAs that may be associated with the vascular disease. The experimental results demonstrate the reliable predictive results of the model and the latent value of the new lncRNA identified for the clinics and treatment of vascular diseases. However, the range of application of this model is very limited, since not every lncRNAs has adjacent genes, even though the lncRNA has adjacent genes, it is likely to be non-functionally associated to its neighboring genes.
In this study, we proposes a decomposition-based least squares method to predict potential lncRNA-disease associations, referred to as ALSBMF. ALSBMF first decomposes the known lncRNA-disease correlation matrix into two characteristic matrices, then defines the optimization function using disease semantic similarity, lncRNA functional similarity and known lncRNA-disease associations and solves two by the least squares method. The optimal feature matrix is finally multiplied by two feature matrices to reconstruct the scoring matrix, filling the missing values of the original matrix to predict the lncRNA-disease associations. This method shows the excellent prediction performance in experimental results.
II. MATERIALS AND METHODS

A. LncRNA-DISEASE ASSOCIATIONS
The known human lncRNA-diseases associations are from the 2012 edition of the LncRNADisease database. Because the results of the experiment need to be tested with the latest data in the case studies, the latest updated data is not used for model training. The lncRNA-disease association data set is pre-processed as follows: (1) deleting the same associated entries that are with different evidence; (2) mapping the disease in the dataset to the MeSH description using the MeSH database. (3) deleting diseases without any MeSH descriptor or tree structure number. (4) screening out data from human species and deleting disease associations that did not pass the screening.
After the above treatment, 242 distinct high quality known lncRNA-disease associations were obtained, including 98 lncRNAs and 122 diseases. This data set is selected as the benchmark data. The LncRNA-disease association network is represented using an adjacency matrix LD, and if lncRNA l i has a correlation with disease d j , LD(i,j) is 1, otherwise 0. The paper also summarizes the characteristics of some basic data sets as shown in Table 1 .
B. DISEASE SEMANTIC SIMILARITY
The Mesh database is a rigorous disease classification system that can be used to effectively study the relationship between Each disease is numbered based on its tree structure in the MeSH database, and can form a directed acyclic graph (DAG). Every disease can transform a homologous directed acyclic graph (DAG), for instance disease d, whose DAG graph can be expressed as DAG(d) = (Anc(d),E(d)), and Anc(d) represents a collection of nodes, including node and its ancestor node; E(d) is the edges that are immediately connected the parent node with the child node and it shows the correlation between different diseases. According to the DAG map of disease, the following two equations show the semantic value contribution of disease nomenclature d to disease D and the semantic value of disease D itself.
is a semantic contribution attenuation factor, indicating that the contribution of these ancestral diseases to the semantic value of disease D slowly decreases as the distance between disease D and its ancestral disease increases. Therefore, disease D is located at the 0th layer, and its semantic value contribution value is 1. The contribution of its ancestral disease ought to be multiplied by the semantic contribution attenuation factor. The value of is set to between 0 and 1, and the value of this paper is 0.5 according to previous studies. According to the method of estimating the semantic similarity of disease, it can recognize that the more ancestral diseases the two diseases share in their DAG, the higher the semantic similarity value they obtain. In this analogy, the following equation shows the semantic similarity between two diseases d 1 and d 2 :
In order to assess the functional similarity between two lncR-NAs (Sun, et and lncRNA l(j) is associated with
The mean first counts the semantic similarity of diseases, for instance, d i1 and a disease group, set D j as
Afterwards, the functional similarity between l(i) and l(j) is computed as
The general workflow of ALSBMF was illustrated in Fig 1. In the process of predicting lncRNA-disease associations, the known lncRNA-disease association matrix actually has many missing values due to the large number of unknown associations, as described above for the user-to-product scoring matrix. Therefore, this paper proposes an alternating least squares method based on matrix decomposition. The potential factor is modified by an alternating least squares algorithm and the model is trained. First, it is assumed that the matrix LD m×n of the known lncRNA-disease associations is approximately decomposed into two characteristic matrices H m×k and W n×k as follows:
where k=50, m and n are the number of lncRNAs and diseases, respectively. H m×k and W n×k in the formula are the hidden feature matrices of lncRNAs and diseases, respectively. In order to make the product of the matrix H m×k and W n×k very close to LD m×n , the minimized square error loss function is defined to solve two characteristic matrices, as follows:
In the formula, R, X and Y are the known lncRNA-disease relationship matrix LD, the lncRNA similarity matrix LS and the disease similarity matrix DS, respectively. HW T -R represents the error between the prediction relationship and the known relationship, and the smaller the error, the closer to the true value. In order to prevent subsequent over-fitting problems, add a regularization term. HH T -X and WW T -Y are a regularization term. H is a hidden feature matrix of lncRNAs, so HH T represents the similarity between lncRNAs, approximately close to the X matrix, and HH T -X represents the error between the two lncRNA similarity matrices. Similarly, W is the hidden feature matrix of diseases, WW T represents the similarity between diseases, approximately close to the Y matrix, and WW T -Y represents the error between the similarity matrices of the two diseases. H 2 + W 2 is also a regularization term. λ 1 and λ 2 are regularization parameters, and their values are discussed later. The equation is detailed as follows:
Matrices H and W that enable the Equation to obtain the minimum are the optimal solutions. Where r ij represents the known relationship between lncRNA l i and disease t j ; h i represents the hidden feature column vector of lncRNA l i , which is the i th row of matrix H; w j represents the hidden feature column vector of disease t j , which is the j th row of matrix W. x ic is the similarity value between lncRNA l i and l c in matrix X. y je is the similarity value between the diseases t j and t e in the matrix Y.
The optimization problem needs to be solved by the ALS algorithm. So the detailed solution process is as follows:
(1) Randomly assign H and W matrices first;
(2) Fixed W and each eigenvector h i in the above formula is an independent variable. Obtain a partial derivative of the objective function with respect to h i and let it be 0 to get:
where r i is the column vector, is the i th row of R m×n , I is the unit matrix of k×k, the x i column vector is the i th row of the matrix X, and each h i feature column vector in the H matrix is as above equation calculation, then solve the matrix H;
(3) Fix H, and similarly, obtain a partial derivative of a w j eigenvector and let its derivative be 0, you get:
where r j is the column vector, which is the j th column of R m×n ; I is the unit matrix of k×k, the y j column vector is the j th row of the matrix Y, and each w j feature column vector in the W matrix is calculated by the above equation, and as a result matrix W is obtained; (4) Repeat steps (2), (3) repeatedly until the maximum number of iterations is reached. From this, the optimal matrices H and W matrices can be obtained, and then the reconstructed predicted score matrix R' is obtained by multiplying H and W matrices as follows:
This fills the missing values of the original matrix to achieve the purpose of identifying potential lncRNA-disease associations.
III. RESULT AND DISCUSSIONS A. PERFORMANCE OF ALSBMF IN PREDICTING LNCRNA-DISEASE ASSOCIATIONS
ALSBMF and the three popular methods GrwLDA, LRLSLDA and Rwrlncd are applied to the known lncRNAdisease association data LD. In particular, the methods in this chapter also use two LOOCV means, global LOOCV and local LOOCV, to access their performance. In global LOOCV, every experimentally verified lncRNA-disease association is choosen as a test sample once, but local LOOCV deems all associations of an lncRNA or those of a disease are chosen as test samples once. Other known lncRNA-disease associations set as training samples. Since Rwrlncd was unable to predict isolated lncRNA-related diseases, it was not used in two local LOOCVs for comparison. A 5-fold cross-validation was also performed for evaluation. Finally, the property of the method is compared by plotting the receiving operating characteristic (ROC) curve and calculating the area under the ROC curve (AUC).
In Figure 2 , the ROC curves for the global LOOCV of ALSBMF, GrwLDA, LRLSLDA and Rwrlncd, are plotted, and their AUC values are calculated. The AUC of ALSBMF is 0.9501, which is clearly better than GrwLDA (0.9443), LRLSLDA (0.8859) and Rwrlncd (0.6867). At the same time, the ROC curve and AUC of local LOOCV for predicting novel lncRNA-related diseases are also plotted for the ALSBMF, GrwLDA and LRLSLDA methods, as shown in Figure 3 . The figure shows that the AUC of ALSBMF is 0.9210, which is higher than GrwLDA (0.8565) and LRLSLDA(0.8256). Finally, the AUC of ALSBMF (0.8268) was significantly higher than those of GrwLDA (0.8217) and LRSLDA(0.7090) in predicting new disease-associated lncRNAs, as shown in Figure 4 . In summary, ALSBMF outperform LRLSLDA and GrwLDA in lncRNA-disease association prediction, novel lncRNA and disease-related predictions. At the same time, this study also conducts five fold cross-validation and executes it 10 times. The average AUC of ALSBMF is 0.9437, and the average AUC of GrwLDA, LRLSLDA, and Rwrlncd are 0.9215, 0.8702, and 0.6775, respectively.
B. EFFECTS OF GAUSSIAN INTERACTION PROFILE KERNEL SIMILARITY FOR LncRNAs AND DISEASES
There are three model parameters in ALSBMF, including k in matrix decomposition and two regularization parameters λ 1 and λ 2 . This article tests the effects of these parameters in LOOCV. In LOOCV, λ 1 is fixed to 10, λ 2 is set to 8 to 12 in turn, with an interval of 1, and k = 50, and the results of their LOOCV are shown in Table 2 . Next, λ 2 is fixed to 10, λ 1 is set to 8 to 12 in turn, with an interval of 1, and, and the results are listed in Table 3 . It can be seen from Table 2 and Table 3  TABLE 2 . Tuning two model parameters: λ 1 = 10 and λ 2 , the value in each cell represents LOOCV AUC. that the smaller the difference between λ 1 and λ 2 , the larger the AUC value; when λ 1 = λ 2 = 10, the difference between them is 0, and the AUC value reaches the highest. Therefore, this paper also sets λ 1 and λ 2 equal in LOOCV, and the values are sequentially changed from 8 to 19 with intervals of 1 and k=50. The results are shown in Table 4 . According to the results in Table 4 , when the value is 17 to 19, the AUC value is stable, so λ 1 and λ 2 are set to 17. In the test of the influence of the parameter k value on the ALSBMF model, λ 1 = λ 2 = 17 is set here in, and k is sequentially set to 10 to 90 variation with an interval of 10, and the results are shown in Table 5 . It can be seen from the table that when k is small, the AUC value is relatively low, which may be the result of missing information; when k=50, the AUC is stable and highest, so k is set to 50.
C. CASE STUDIES PREDICTING LNCRNA-DISEASE ASSOCIATIONS
ALSBMF was used to predict all disease-associated lncRNAs studied in this study. Inferring potential lncRNA-disease associations via ALSBMF can provide an important complement to experimental research. In particular, there is ample evidence that lncRNA plays an important role in various human cancers. Therefore, this study conducts case studies of three important cancers to show the predictive performance of ALSBMF. The prediction results of three cancer-associated lncRNAs were confirmed based on recent literature and the latest LncRNADisease database. The top three lncRNAs predicted by the three diseases are listed in Table 6 . The three diseases are colon cancer, kidney cancer and liver cancer.
Colon cancer is one of the most popular malignant tumors in the world and poses a huge menace to public fitness. In recent years, the prevalence of colon cancer has risen sharply in China due to changes in human lifestyles (Xue et al., 2015) . In patients with stage II colon cancer, management after surgical resection remains a clinical dilemma, with only 80% of patients cured by surgery (Dorbeau et al., 2017) . Despite intensive research and treatment improvements, more than 50% of colon cancer patients die from this disease, highlighting the need to unravel the unknown mechanisms that lead to the development of colon cancer malignancies (Hsiao et al., 2017) . Biological experiments have found that there are some important associations between the evolution of colon cancer and the mutations and disorders of lncRNAs. ALSBMF predicts potential colon cancer-associated lncRNAs. All of the first three colon cancer-associated lncRNAs predicted by ALSBMF were verified by the latest update of the LncRNADisease database and literature. For instance, some studies have shown that CRNDE expression in colon cancer tissues is higher than in common colon mucosa (Yu et al., 2017) . HOTAIR expression is up-regulated in colon carcinoma, indicating that HOTAIR is crucial to the evolution, progression and transfer of colon cancer (Luo et al., 2016) . HOTAIR acts as an oncogene and represents a novel molecular target for the therapy of colon carcinoma. In the study, it was confirmed that MALAT1 is up-regulated in human colon cancer cell lines(Jie and Zhao, 2017) . Furthermore, inhibition of MALAT1 inhibited the proliferation of colon cancer SW480 and HCT116 cells, suggesting that MALAT1 can be an important prognostic biomarker in the development of colon cancer.
Kidney cancer is not a simple disease, it contains many diverse cancers that happen in the kidney. Every cancer has a diverse histological and clinical process and responds variously to treatment, even if they are caused by mutations in different genes (Linehan et al., 2010) . In the United States, kidney cancer accounts for 2% to 3% of new cancer cases. More than 80% of kidney cancers are derived from the renal parenchyma, which is composed of adenocarcinoma (renal cell carcinoma). In the United States, renal cell carcinoma is the fastest-growing rate among all types of tumors (Chow et al., 2000) . Similarly, ALSBMF performed well in predicting renal cancer-associated lncRNAs because all of the top three forecast lncRNAs were verified by the latest LncRNADisease database and literature. For instance, studies have shown that KCNQ1DN and IGF2, which are far from the H19/IGF2 region, may play a role in nephroblastoma together (Xin et al., 2008) . WT1 is a well characterized developmental gene that is mutated in nephroblastoma and acute myeloid leukemia and has an antisense transcript (WT1-AS). WT1-AS is dysregulated in nephroblastoma by epigenetic defects (Dallosso et al., 2007) . In nephroblastoma of childhood renal tumors, loss of expression pattern of H19/IGF2 blot results in silencing of H19 and biallelic expression of IGF2. Epigenetic H19 silencing is an early event in the development of nephroblastoma (Frevel et al., 1999) .
Liver cancer, also known as primary liver cancer, is a cancer that begins in the liver. Cancer that spreads from other places to the liver, that is, liver metastasis, is more common than cancer that begins in the liver. Primary liver cancer is the sixth largest cancer in the world (6%) and the second reason of cancer death (9%). In 2015 it killed 810,500 people. In 2015, 263,000 people who died of liver cancer died of hepatitis B and 167,000 died of hepatitis C(Mortality and Causes of Death, 2016). Similarly, the first three liver cancer-associated lncRNA candidates predicted by ALSBMF were validated by the latest LncRNADisease database and literature. For instance, studies have indicated that HOTAIR promotes the malignant growth of human liver cancer stem cells by down-regulating SETD2 (Haiyan et al., 2015) . MEG3 plays a tumor suppressive role by negatively regulating the activity of PKM2 and β-catenin signaling pathway in liver cancer, and provides a latent treatment target for the remedy of liver carcinoma (Zheng et al., 2018) . MALAT1 is highly expressed in human hepatocellular carcinoma tissues, and the overexpression of MALAT1 can significantly promote the growth of liver cancer cells. The haplosome deficiency of MALAT1 plays an important role in the malignant growth of liver cancer stem cells (Wu et al., 2016) .
D. CASE STUDIES ON PREDICTED NOVEL DISEASES AND NOVEL LncRNAs
In order to evaluate the performance of ALSBMF to predict new disease-associated lncRNAs, we eliminate the known associations of a diseases with all lncRNAs. Two diseases were selected here: breast carcinoma and nasopharyngeal carcinoma (see Table 7 ). It shows that the top five forecast lncRNAs related with breast carcinoma are validated by the dbSNP, PubMed and PubMed Central. The database confirmed the predicted top five lncRNAs associated with colon carcinoma and breast carcinoma.
Similarly, in order to test the ability of ALSBMF to predict new lncRNA-associated diseases, all foregone lncRNAdisease associations with a certain lncRNA were deleted. In this study, lncRNA MALAT1 and H19 were selected as case studies (see Table 8 ). In both cases, the predicted top five MALAT1 and H19-related diseases were verified by databases and literature. In conclusion, ALSBMF has shown favorable performance in predicting new disease-associated lncRNAs and new lncRNA-related diseases.
IV. CONCLUSION
Biological experiments have been the primary method for identifying lncRNA-disease associations. However, with the increase in the amount of latest founded lncRNAs per year, experimental-based validation means have encountered many bottlenecks. Luckily, the existence of a large number of biological data sets associated with lncRNAs in various publicly available databases makes computational prediction possible. Given the limitations of biological assays and a large number of biological datasets, there is an urgent need to develop computational models to efficiently identify potential lncRNA-disease associations and lncRNA signatures for disease diagnosis, treatment outcome prediction, and therapeutic evaluation, and for biological experiments. Research supplies a meaningful complement. This study also proposes a matrix decomposition-based least squares method to predict potential lncRNA-disease associations, referred to as ALSBMF. ALSBMF first decomposes the known lncRNA-disease correlation matrix into two characteristic matrices, then defines the optimization function using disease semantic similarity, lncRNA functional similarity and known lncRNA-disease associations and solves two by least squares method. The optimal feature matrix is finally multiplied by two feature matrices to reconstruct the scoring matrix, filling the missing values of the original matrix to predict the potential lncRNAdisease associations. ALSBMF is superior to the three comparison means in predicting veracity, and the forecast new lncRNA-disease associations is verified by literature. However, ALSBMF has some drawbacks. First, there are fewer known lncRNA-disease association numbers and lncRNA-related information. Second, the lncRNA functional similarity is calculated based on disease semantic similarity and known lncRNA-disease associations, so ALSBMF may lead to biased predictions. Finally, the parameter optimization of ALSBMF is also a problem that needs to be solved. 
